Miramar Labs (KTLC) 10-Q 9 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	9 Months Ended
	Sep. 30, 2016	Nov. 08, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Miramar Labs, Inc.
Entity Central Index Key	1,586,727
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,380,653

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 6,073,680	$ 2,642,509
Accounts receivable, net	3,102,629	2,683,053
Inventories	5,613,145	4,791,741
Prepaid expenses and other current assets	641,220	290,481
Total current assets	15,430,674	10,407,784
Property and equipment, net	783,942	1,211,129
Restricted cash	295,067	295,067
Other noncurrent assets	13,976	11,860
TOTAL ASSETS	16,523,659	11,925,840
Current liabilities:
Notes payable, net of discount	9,939,261	10,829,375
Accounts payable	1,432,136	1,288,107
Accrued and other current liabilities	4,513,318	3,572,441
Deferred revenue	228,955	739,786
Total current liabilities	16,113,670	16,429,709
Warrant liability	54,029	499,616
Deferred rent, noncurrent	87,010	112,065
Capital lease payable, noncurrent	0	16,865
TOTAL LIABILITIES	16,254,709	17,058,255
Commitments and contingencies (Note 6)
Redeemable convertible preferred stock, $.001 par value - 40,000,000 shares authorized and 2,826,981 shares issued and outstanding at December 31, 2015 (Liquidation preference of $61,179,942). No shares authorized or outstanding at September 30, 2016	0	61,179,942
Stockholders’ equity (deficit):
Common stock, $0.001 par value - 100,000,000 and 105,500,000 shares authorized and 9,380,653 and 398,540 shares issued and outstanding at September 30, 2016 and December 31, 2015	9,381	399
Additional paid-in capital	110,711,248	27,133,634
Accumulated deficit	(110,451,679)	(93,447,128)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	268,950	(66,312,357)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	16,523,659	11,925,840
Blank check preferred stock
Stockholders’ equity (deficit):
Convertible preferred stock	0	0
Series A convertible preferred stock
Stockholders’ equity (deficit):
Convertible preferred stock	0	148
Series B convertible preferred stock
Stockholders’ equity (deficit):
Convertible preferred stock	$ 0	$ 590

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Redeemable convertible preferred stock, par value (usd per share)		$ 0.001
Redeemable convertible preferred stock, shares authorized (shares)	0	40,000,000
Redeemable convertible preferred stock, shares issued (shares)		2,826,981
Redeemable convertible preferred stock, shares outstanding (shares)	0	2,826,981
Redeemable convertible preferred stock, liquidation preference		$ 61,179,942
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	100,000,000	105,500,000
Common stock, shares issued (shares)	9,380,653	398,540
Common stock, shares outstanding (shares)	9,380,653	398,540
Blank check preferred stock
Convertible preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized (shares)	5,000,000	5,000,000
Convertible preferred stock, shares issued (shares)	0	0
Convertible preferred stock, shares outstanding (shares)	0	0
Series A convertible preferred stock
Convertible preferred stock, par value (usd per share)		$ 0.001
Convertible preferred stock, shares authorized (shares)	0	2,100,000
Convertible preferred stock, shares issued (shares)		147,864
Convertible preferred stock, shares outstanding (shares)	0	147,864
Convertible preferred stock, liquidation preference		$ 2,000,000
Series B convertible preferred stock
Convertible preferred stock, par value (usd per share)		$ 0.001
Convertible preferred stock, shares authorized (shares)	0	9,000,000
Convertible preferred stock, shares issued (shares)		589,784
Convertible preferred stock, shares outstanding (shares)	0	589,784
Convertible preferred stock, liquidation preference		$ 14,359,244

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenue	$ 4,303,307	$ 3,793,241	$ 16,035,338	$ 11,822,320
Cost of revenue	1,787,770	1,742,357	7,211,110	5,745,297
Gross margin	2,515,537	2,050,884	8,824,228	6,077,023
Operating expenses:
Research and development	817,488	1,192,019	2,562,481	3,941,360
Selling and marketing	3,448,976	2,736,610	9,975,248	8,980,820
General and administrative	1,871,739	1,313,436	4,716,991	3,907,822
Total operating expenses	6,138,203	5,242,065	17,254,720	16,830,002
Loss from operations	(3,622,666)	(3,191,181)	(8,430,492)	(10,752,979)
Interest income	4,035	1,214	7,764	5,001
Interest expense	(285,615)	(481,194)	(948,662)	(1,025,013)
Loss on debt conversion	0	0	(8,062,001)	0
Other income, net	(9,929)	11,252	438,148	88,104
Net loss before provision for income taxes	(3,914,175)	(3,659,909)	(16,995,243)	(11,684,887)
Provision for income taxes	(7,783)	(7,297)	(9,308)	(8,722)
Net and comprehensive loss	(3,921,958)	(3,667,206)	(17,004,551)	(11,693,609)
Accretion of redeemable convertible preferred stock	0	(20,000)	0	(63,117)
Net loss attributable to common stockholders	$ (3,921,958)	$ (3,687,206)	$ (17,004,551)	$ (11,756,726)
Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted	9,256,362	385,271	4,030,810	385,271
Net loss per share attributable to common stockholders, basic and diluted (usd per share)	$ (0.42)	$ (9.57)	$ (4.22)	$ (30.52)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) Statement - USD ($)	Total	Convertible notesFebruary 2016 Notes	Convertible notesMay 2016 Notes	Exercise Price $6.63 - $8.66 [Member]	Exercise Price $1.36 [Member]	Convertible Preferred Stock	Common Stock	Common StockConvertible notesFebruary 2016 Notes	Common StockConvertible notesMay 2016 Notes	Common StockExercise Price $6.63 - $8.66 [Member]	Common StockExercise Price $1.36 [Member]	Additional Paid-In Capital	Additional Paid-In CapitalConvertible notesFebruary 2016 Notes	Additional Paid-In CapitalConvertible notesMay 2016 Notes	Additional Paid-In CapitalExercise Price $6.63 - $8.66 [Member]	Additional Paid-In CapitalExercise Price $1.36 [Member]	Accumulated Deficit
Redeemable Convertible Preferred Stock, Beginning Balance (shares) at Dec. 31, 2014	2,826,981
Redeemable Convertible Preferred Stock, Beginning Balance at Dec. 31, 2014	$ 61,179,942
Redeemable Convertible Preferred Stock
Series D redeemable preferred stock issuance cost	(3,117)
Accretion of redeemable convertible preferred stock to redemption value	$ 3,117
Redeemable Convertible Preferred Stock, Ending Balance (shares) at Dec. 31, 2015	2,826,981
Redeemable Convertible Preferred Stock, Ending Balance at Dec. 31, 2015	$ 61,179,942
Stockholders' Equity Beginning Balance (shares) at Dec. 31, 2014						737,648	385,294
Stockholders' Equity Beginning Balance at Dec. 31, 2014	(52,473,002)					$ 738	$ 385					$ 26,478,755					$ (78,952,880)
Stockholders' Equity (Deficit)
Exercise of stock options (shares)							13,246
Exercise of stock options	51,093						$ 14					51,079
Accretion of redeemable convertible preferred stock to redemption value	(3,117)											(3,117)
Stock-based compensation	606,917											606,917
Net and comprehensive loss	(14,494,248)																(14,494,248)
Stockholders' Equity Ending Balance (shares) at Dec. 31, 2015						737,648	398,540
Stockholders' Equity Ending Balance at Dec. 31, 2015	$ (66,312,357)					$ 738	$ 399					27,133,634					(93,447,128)
Redeemable Convertible Preferred Stock
Conversion of preferred stock to common stock in connection with the merger (shares)	(2,826,981)
Conversion of preferred stock to common stock in connection with the merger	$ (61,179,942)
Redeemable Convertible Preferred Stock, Ending Balance (shares) at Sep. 30, 2016	0
Redeemable Convertible Preferred Stock, Ending Balance at Sep. 30, 2016	$ 0
Stockholders' Equity (Deficit)
Exercise of stock options (shares)										3,267	18,483
Exercise of stock options				$ 24,622	$ 25,137					$ 3	$ 19				$ 24,619	$ 25,118
Issuance of restricted common stock at $5.5925 per share for consulting services in August 2016 (shares)							63,636
Issuance of restricted common stock at $5.5925 per share for consulting services in August 2016	355,885						$ 63					355,822
Issuance of common stock, net of offering costs of $831,117 (shares)							1,568,726
Issuance of common stock, net of offering costs of $831,117	7,057,177						$ 1,569					7,055,608
Issuance of common stock for conversion of convertible securities (shares)						(737,648)	3,611,857	2,418,628	409,841
Issuance of common stock for conversion of convertible securities	61,179,942	$ 12,093,051	$ 2,049,294			$ (738)	$ 3,612	$ 2,418	$ 410			61,177,068	$ 12,090,633	$ 2,048,884
Issuance of common stock to KTL Bamboo International Corp (shares)							900,000
Issuance of common stock to KTL Bamboo International Corp	0						$ 900					(900)
Common stock repurchased in connection with the merger (shares)							(12,325)
Common stock repurchased in connection with the merger	(61,696)						$ (12)					(61,684)
Conversion of convertible preferred stock warrants to common stock warrants	53,436											53,436
Issuance of common stock warrants for issuance costs	(44,663)											(44,663)
Stock-based compensation	853,673											853,673
Net and comprehensive loss	(17,004,551)																(17,004,551)
Stockholders' Equity Ending Balance (shares) at Sep. 30, 2016						0	9,380,653
Stockholders' Equity Ending Balance at Sep. 30, 2016	$ 268,950					$ 0	$ 9,381					$ 110,711,248					$ (110,451,679)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Parenthetical) - USD ($)	1 Months Ended			9 Months Ended
	Sep. 30, 2016	Apr. 30, 2016	Oct. 31, 2015	Sep. 30, 2016	Aug. 31, 2016
Common Stock
Options exercised (usd per share)	$ 1.36
Share price (usd per share)					$ 5.5925
Offering costs				$ 831,117
Minimum
Options exercised (usd per share)		$ 6.63	$ 1.35
Maximum
Options exercised (usd per share)		$ 8.66	$ 8.66

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (17,004,551)	$ (11,693,609)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	411,132	526,904
Loss on debt conversion	8,062,001	0
Loss on disposal of fixed assets	0	1,475
Stock-based compensation	853,673	464,792
Issuance of restricted common stock	355,885	0
Change in preferred stock warrant value	(436,814)	(92,596)
Amortization of debt discount and issuance costs	290,549	138,612
Changes in operating assets and liabilities
Accounts receivable	(419,576)	728,321
Inventories	(653,261)	163,739
Prepaid expenses and other current assets	(350,739)	6,806
Other noncurrent assets	(2,116)	0
Accounts payable	144,029	(73,576)
Accrued and other current liabilities	927,918	410,171
Deferred revenue	(510,831)	(207,578)
Net cash used in operating activities	(8,332,701)	(9,626,539)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(152,088)	(156,466)
Net cash used in investing activities	(152,088)	(156,466)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of common stock	7,106,936	0
Repurchase of common stock	(61,696)	0
Redeemable convertible preferred stock issuance costs	0	(63,117)
Proceeds from issuance of notes payable	5,145,067	2,296,079
Principal payments on capital leases	(28,961)	(40,872)
Payments on notes payable	(245,386)	(2,252,127)
Net cash provided by (used in) financing activities	11,915,960	(60,037)
Net increase (decrease) in cash and cash equivalents	3,431,171	(9,843,042)
Cash and cash equivalents at beginning of period	2,642,509	13,484,740
Cash and cash equivalents at end of period	6,073,680	3,641,698
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	598,385	909,021
Cash paid for taxes	9,308	8,722
DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accretion of redeemable preferred stock to redemption value	0	63,117
Net transfer to inventory from leased equipment	(168,143)	(138,351)
Conversion of preferred stock and warrants to common stock and warrants	76,827,313	0
Common stock issued to convert notes payable	14,142,345	0
Issuance of common stock warrants for issuance costs	$ 44,663	$ 234,719

Background and Organization

Background and Organization	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Organization	Background and Organization On June 7, 2016 (the “ Closing Date ”), the Company, Acquisition Sub and Miramar entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”). Pursuant to the terms of the Merger Agreement, Acquisition Sub merged with and into Miramar, and Miramar became the surviving corporation and thus became the Company’s wholly-owned subsidiary (the “ Merger ”). Prior to the Merger, the Company discontinued its prior business of distributing water filtration systems produced in China, and acquired the business of Miramar, which designs, manufactures and markets the miraDry System, which is designed to eliminate axillary, or underarm, sweat. At the Closing Date, each of the shares of Miramar’s common stock and preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into shares of the Company’s common stock at a ratio of 1: 0.07393 (the “ Conversion Ratio ”). Additionally, warrants to purchase shares of Miramar’s Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock issued and outstanding immediately prior to the closing of the Merger were converted into warrants to purchase shares of the Company’s common stock at the Conversion Ratio. The Merger was treated as a recapitalization and reverse acquisition of the Company for financial accounting purposes. Miramar is considered the acquirer for accounting purposes, and the Company’s historical financial statements before the Merger will be replaced with the historical financial statements of Miramar before the Merger in future filings with the SEC. For more details on the Merger, please see Item 2.01 of our Current Report on Form 8-K filed with the SEC on June 13, 2016, as amended on June 14, 2016. The Company and its wholly-owned subsidiary, Miramar, develop clinical systems to address hyperhidrosis. In January 2011, Miramar received approval from the U.S. Food and to Drug Administration (the “ FDA ”), to market the miraDry System to eliminate underarm sweat glands. The Company’s principal markets are the United States, Asia-Pacific and Europe/Middle East. During 2012, Miramar Technologies, Inc. commercially launched its first product, the miraDry System, a clinical system to address hyperhidrosis. Miramar has a wholly-owned subsidiary, Miramar Labs HK Limited, which was incorporated under the laws of Hong Kong in January 2013. Miramar Labs HK Limited commenced its operations during 2013 to oversee operations in Asia and is located in Hong Kong. The accompanying unaudited condensed financial statements have been prepared in accordance with the rules and regulations of the SEC, for interim financial information and, accordingly, do not include all of the information and footnotes required by generally accepted accounting principles in the United States (“ GAAP ”) for complete financial statements. These condensed consolidated financial statements are prepared on the same basis and should be read in conjunction with the audited financial statements and related notes included in the Company’s financial statements for the year ended December 31, 2015. Interim results are not necessarily indicative of the results to be expected for the full year, and no representation is made thereto. In the opinion of management, these financial statements include all adjustments necessary to state fairly the financial position and results of operations for each interim period shown. All such adjustments occur in the ordinary course of business and are of a normal, recurring nature. The accompanying financial statements are prepared on a going concern basis which contemplates the realization of assets and discharge of liabilities in the normal course of business. Since inception, Miramar Labs, Inc. had incurred net losses and negative cash flows from operations. From April 4, 2006 (date of inception) to September 30, 2016 , Miramar Labs, Inc. had an accumulated deficit of $110,451,679 . The Company has not achieved positive cash flows from operations. To date, the Company has been funded primarily by preferred stock and debt financings. In order to continue its operations, the Company must raise additional equity or debt financing and achieve profitable operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be able to obtain additional equity or debt financing on terms acceptable to the Company, or at all. The failure to obtain sufficient funds on acceptable terms, when needed, could have a material, adverse effect on the Company’s business, results of operations, and future cash flows. To achieve profitable operations, the Company must successfully continue to develop, enhance, manufacture, and market its products. There can be no assurance that any such products can continue to be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position and future cash flows.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Intercompany balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s most significant estimates relate to inventory valuation and reserves, warranty accruals, deferred tax asset valuation allowance and valuation of equity and equity-linked instruments (common stock, options and warrants). Our management believes that we consistently apply these judgments and estimates and the consolidated financial statements and accompanying notes fairly represent all periods presented. However, any differences between these judgments and estimates and actual results could have a material impact on our consolidated statements of income and financial position. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents are deposited with one financial institution in the United States of America. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents. At September 30, 2016 , the Company’s uninsured cash balances totaled $6,101,499 . The Company performs periodic credit evaluations of its customers’ financial condition and generally requires deposits from its customers. The Company generally does not charge interest on past due accounts. The Company’s customers representing greater than 10% of accounts receivable and revenue were as follows: Revenue Accounts Receivable Nine Months Ended September 30, September 30, December 31, 2016 2015 2016 2015 Customer A 12% * * * Customer B * * 28% * Customer C * * 11% 12% Customer D * 15% * 20% Customer E * * * 23% Sales in North America consisted of 46% and 44% of total revenue, in the nine month periods ended in September 30, 2016 and 2015 , respectively. The remainder of the Company’s sales came primarily from Asia-Pacific and Europe/Middle East. Generally, the second quarter tends to be stronger than the third quarter, when vacations and holidays are more prevalent in North America and Europe. Amplifiers used in the production of the miraDry system are manufactured in the United States and consumables (“ bioTips ”) are manufactured in China. These single source suppliers of these critical components may not be replaced without significant effort and delay in production. If the operations of these manufacturers are interrupted or if they are unable to meet our delivery requirements due to capacity limitations or other constraints, the Company may be limited in its ability to fulfill customer orders or to repair equipment at current customer sites. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2016 , as compared to the significant accounting policies described in the Company’s financial statements for the year ended December 31, 2015, filed on Form 8-K on June 13, 2016. Recent Accounting Pronouncements There were no changes to the new accounts pronouncements as described in the Company’s financial statements for the year ended December 31, 2015, filed on Form 8-K on June 13, 2016, except for the following: In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments .” This update provides guidance on the required presentation and classification in the statement of cash flows for various issues for which there has been diversity in practice in the past. For public entities, the new standard is effective for annual periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company is currently evaluating the effect that the standard will have on the consolidated financial statements.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Inventories September 30, 2016 December 31, 2015 (Unaudited) Raw materials $ 2,365,170 $ 2,132,655 Work in progress 1,960,245 1,263,019 Finished goods 1,287,730 1,396,067 $ 5,613,145 $ 4,791,741 Property and Equipment, Net September 30, 2016 December 31, 2015 (Unaudited) Leasehold Improvements $ 844,360 $ 844,360 Machinery and equipment 1,508,074 1,355,986 Computer and office equipment 241,291 241,291 Software 326,992 326,992 Furniture and fixtures 114,564 114,564 Leased equipment — 168,143 3,035,281 3,051,336 Less: Accumulated depreciation and amortization (2,251,339 ) (1,840,207 ) $ 783,942 $ 1,211,129 No capital leases were entered into during the year ended December 31, 2015 or the nine month period ended September 30, 2016 . Depreciation and amortization expense was $411,132 and $526,904 for the nine -month periods ended September 30, 2016 and 2015 , respectively. There was no leased equipment at September 30, 2016 due to the discontinuation of the Market Validation Program. At September 30, 2016 and December 31, 2015 , substantially all of the property and equipment was located at the Company’s corporate headquarters in the United States. Accrued Liabilities September 30, 2016 December 31, 2015 (Unaudited) Accrued payroll and related expenses $ 1,795,317 $ 1,457,534 Accrued royalty 1,740,520 1,226,973 Accrued warranty 181,000 217,000 Accrued marketing 286,620 165,600 Accrued clinical expenses 11,500 2,600 Accrued legal 67,200 112,000 Capital lease payable, current 21,814 33,909 Deferred rent, current 30,705 18,672 Accrued other expenses 378,642 338,153 $ 4,513,318 $ 3,572,441 Accrued Warranty The Company regularly reviews the accrued warranty balance and updates as necessary based on sales and warranty trends. The warranty accrual as of September 30, 2016 and December 31, 2015 consisted of the following activity: Warranty accrual, December 31, 2014 $ 253,000 Accruals for product warranty 427,467 Cost of warranty claims (463,467 ) Warranty accrual, December 31, 2015 $ 217,000 Accruals for product warranty 303,738 Cost of warranty claims (339,738 ) Warranty accrual, September 30, 2016 $ 181,000

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair Value Measurements are determined under a three-level hierarchy for fair value measurements that prioritizes the inputs to valuation techniques used to measure fair value, distinguishing between market participant assumptions developed based on market data obtained from sources independent of the reporting entity (the observable inputs) and the reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (the unobservable inputs). Fair value is the price that would be received to sell an asset or would be paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company primarily uses prices and other relevant information generated by market transactions involving identical or comparable assets. The Company also considers the impact of a significant decrease in volume and level of activity for an asset or liability when compared with normal activity to identify transactions that are not orderly. The highest priority is given to unadjusted quoted prices in active markets for identical assets ( Level 1 measurements) and the lowest priority to unobservable inputs ( Level 3 measurements). Securities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The three hierarchy levels are defined as follows: Level 1 Quoted prices in active markets that are unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities identical assets and liabilities; Level 2 Quoted prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in active markets or financial instruments for which significant inputs are observable, either directly or indirectly; Level 3 Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The fair value of the Company’s financial assets and liabilities measured on a recurring basis, as of September 30, 2016 and December 31, 2015 , were as follows: September 30, 2016 Level 1 Level 2 Level 3 Total Liabilities Warrant liability $ — $ — $ 54,029 $ 54,029 December 31, 2015 Level 1 Level 2 Level 3 Total Liabilities Warrant liability $ — $ — $ 499,616 $ 499,616 There were no transfers between Level 1, 2 and 3 of the fair value hierarchy during the nine months ended September 30, 2016 and 2015 . Assumptions used in valuing the warrant liabilities are discussed in Note 10 below. The principal assumptions used, and their impact on valuations were as follows: Stock Price - As a private company, there was no actively traded market for the Company’s stock and the Company used commonly accepted valuation techniques such as the discounted cash flows, market comparables and recent actual stock sales to derive an estimate of the fair value of its stock. An increase in value of the stock will increase the value of the warrant liability. Upon closing of the Merger, the Company became a publicly traded company and began using its publicly traded stock price. Risk-Free Interest Rate - This is the U.S. Treasury rate for the measurement date having a term equal to the weighted average expected remaining term of the instrument. An increase in the risk-free interest rate will increase the fair value of the warrant liability. Expected Remaining Term - This is the period of time over which the instrument is expected to remain outstanding and is based on management’s estimate, taking into consideration the remaining contractual life, historical experience and the possibility of liquidation. An increase in the expected remaining term will increase the fair value of the warrant liability. Expected Volatility - This is a measure of the amount by which the Company’s common stock price has fluctuated or is expected to fluctuate. The Company uses the historic volatility of a group of comparable peer publicly traded companies over the retrospective period corresponding to the expected remaining term of the instrument on the measurement date. An increase in the expected volatility will increase the fair value of the warrant liability. Since the Company is newly public, it does not have sufficient trading history to estimate it’s own volatility. Dividend Yield - The Company has not made any dividend payments and does not plan to pay dividends in the foreseeable future. An increase in the dividend yield will decrease the fair value of the warrant liability. The changes in the warrant liability are summarized below: Fair value at December 31, 2014 $ 371,039 Fair value of warrants issued during the year 234,719 Change in fair value recorded in interest and other income, net (106,142 ) Fair value at December 31, 2015 $ 499,616 Fair value of warrants issued during the year 44,663 Conversion to common stock warrants (53,436 ) Change in fair value recorded in interest and other income, net (436,814 ) Fair value at September 30, 2016 $ 54,029

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Miramar Technologies, Inc. was formed at an incubator, The Foundry, LLC, or The Foundry, a company which provides seed capital and management services to its investees. Certain employees of The Foundry serve as members of the Company’s Board of Directors (the “ Board ”) and own shares of our common stock. The total amount reimbursed to The Foundry for services provided as members of the Board was $46,976 and $47,051 , for the nine months ended September 30, 2016 and 2015 , respectively. In February 2008, Miramar Technologies, Inc. entered into a technology license and royalty agreement with The Foundry wherein Miramar Technologies, Inc. agreed to pay The Foundry a royalty of 1.5% of sales of the licensed products and 1.5% of the patented products, up to a maximum of $30 million . In March 2013, the total royalty percentage increased from 1.5% to 3.0% due to the issuance of a patent covering certain products of the Company. The total amount payable to The Foundry as of September 30, 2016 and December 31, 2015 was $1,740,520 and $1,226,973 , respectively, which included interest accrued at the annual interest rate of the prime rate quoted by the Wall Street Journal plus 1% beginning on the first day of the calendar quarter to which such payment relates. No royalties were paid during the nine months ended September 30, 2016 or in the year ended December 31, 2015 .

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. The Company has entered into indemnification agreements with its directors and certain executive officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors and officers, other than liabilities arising from willful misconduct of the individual. No liability associated with such indemnifications has been recorded at September 30, 2016 or December 31, 2015 . Legal Claims On July 20, 2015, a lawsuit alleging product liability, breach of warranty and negligence was filed against the Company in the Orange County Superior Court. The plaintiff alleged, among other things, that the Company was liable to plaintiff for injuries suffered due to defects in a certain miraDry device. We believe that there is no merit to the claims against the Company and the Company intends to vigorously defend the lawsuit, but the outcome of any potential litigation matter is uncertain. Management does not believe that resolution of this matter will have a material negative effect on our operating results. As of September 30, 2016 or December 31, 2015 , no amounts have been accrued related to the matters as we believe the risk of material loss to be remote. In September 2016, the Company received a demand from an attorney in Japan who represents a terminated employee claiming wrongful termination. While we believe that the claim lacks legal basis and that we would prevail on the merits, the outcome is somewhat uncertain until the matter is finally resolved or adjudicated. The Company is insured,with a deductible payment immaterial to our operating results, to cover such claims. Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is probable that a liability has been incurred, and when the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s consolidated financial statements. Contingencies are inherently unpredictable and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Other than the foregoing, we are currently not aware of any other pending legal proceedings to which we are a party or of which any of our property is the subject, nor are we aware of any such proceedings that are contemplated by any governmental authority. FDA Inspection The FDA performed a routine inspection from July 25, 2016 through August 1, 2016. A Form FDA 483 listing one observation related to complaint handling and reporting and a second observation related to the documentation of CAPA activities was issued. The observations were corrected with a response letter submitted to FDA. FDA has indicated the issues will be reviewed during the next routine inspection. Operating and Capital Leases Rent expense under the Company’s operating leases was $429,685 and $424,912 for the nine -month periods ended September 30, 2016 and 2015 , respectively. The Company recognizes rent expense on a straight-line basis over the lease period. The difference between rent payable and rent expense on a straight-line basis is recorded as deferred rent and amortized over the period of the lease. The aggregate future minimum lease payments under all leases are as follows: Operating Lease Capital Leases Three months ended December 31, 2016 $ 135,014 $ 5,256 Year ending December 31, 2017 552,207 17,249 Year ending December 31, 2018 568,773 — Year ending December 31, 2019 241,592 — Total minimum lease payments $ 1,497,586 22,505 Less: Amount representing interest (691 ) Present value of minimum lease payments 21,814 Less: current portion of capital leases (21,814 ) Long term portion of capital leases $ —

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Notes Payable	Notes Payable In August 2015, the Company refinanced the outstanding balance of the $10 million loan and security agreement entered into in June 2013. The new agreement provided for the issuance of secured promissory notes in the aggregate principal amount of up to $20 million to be drawn down in two additional tranches of $5 million each, subject to certain financial milestones. The refinanced $10 million promissory note accrues interest at 7.80% per annum and monthly interest payments commenced on September 1, 2015. Principal and interest payments will commence on January 1, 2017. All borrowings under the agreement are collateralized by substantially all of the Company’s assets. There are no significant financial covenants. The agreement contains a subjective acceleration clause. Failure to comply with the loan covenants may result in the acceleration of payment of all outstanding principal and interest amounts plus a prepayment fee. Due to the subjective acceleration clause, the outstanding notes payable are classified as current in the accompanying Consolidated Balance Sheets. As of September 30, 2016 , the Company was in compliance with the debt covenants. In December 2015, the Company entered into a note purchase agreement with existing private investors to draw down up to $1.5 million for working capital purposes. The Company subsequently issued $1.3 million of convertible promissory notes (“ December 2015 Notes ”). In February 2016, the Company entered into another note purchase agreement (“ February 2016 NPA ”) with existing private investors to draw down up to $2.7 million for working capital purposes. If the investors agreed to purchase the full amount available under the February 2016 NPA, the December 2015 Notes would be canceled and the February 2016 NPA would be increased by the outstanding principal and interest due on the December 2015 Notes. The Company subsequently canceled and reissued $1.3 million of the December 2015 Notes and issued $2.7 million of convertible promissory notes (“ February 2016 Notes ”). In May 2016, the Company increased the aggregate principal amount of the notes that may be issued under the February 2016 Notes from $2.7 million to $4.85 million and subsequently issued $2.0 million of additional convertible promissory notes. Per the terms of the notes, interest was accrued at 8% per year and were due at the earliest of a liquidation event or one year from date of issuance. In the event of a qualified equity financing, the outstanding principal and interest on the notes payable would automatically convert into shares of the qualified financing shares at a price equal to the price per share paid by the investors in the qualified equity financing. In the event of a non-qualified financing, the shares would be converted at the option of the majority of the investors. If there was no financing event prior to the maturity date, the outstanding principal and interest on the notes payable would automatically convert into shares of Series D preferred stock at $21.64 per share. In June 2016, in connection with the Merger, $6 million of outstanding notes were converted into 2,828,469 shares of common stock. The notes that were not converted according to their original conversion terms incurred a loss on debt conversion of $8,062,001 . The Company entered into short term financing agreements for insurance premiums with nine month payment terms and interest rates ranging from 2.25% to 4.95% . The outstanding balance of the financing agreements was $217,038 at September 30, 2016 and $40,889 at December 31, 2015 . Annual future principal payments under the notes payable are as follows: Three months ended December 31, 2016 $ 131,293 Year ending December 31, 2017 3,477,349 Year ending December 31, 2018 3,665,814 Year ending December 31, 2019 2,942,582 Total payments 10,217,038 Less: Unamortized debt discount (277,777 ) Carrying value of notes payable $ 9,939,261

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Common Stock	Common Stock The Company’s amended Articles of Incorporation authorize the Company to issue 100,000,000 shares of $0.001 common stock. The common stockholders are entitled to elect three members to the Board. The holders of common stock are also entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board. As of September 30, 2016 , no dividends have been declared to date. In connection with the Merger, 1,568,726 shares of common stock were issued in exchange for cash proceeds, net of issuance costs, of $7,057,177 and 900,000 shares were issued to the shareholders of KTL Bamboo International Corp. At September 30, 2016 , the Company had reserved common stock for future issuance as follows: Exercise of options under stock plan 1,378,546 Issuance of options under stock plan 103,703 Exercise of common stock warrants 84,428 Common stock reserved for future issuance 1,566,677 Stock Warrants From June to August 2016, the Company issued warrants to purchase 17,504 shares of the common stock in conjunction with the Merger at an exercise price of $5.00 . The Company determined the value of the warrants on the date of issuance to be $44,663 using the Black-Scholes option pricing model. Assumptions used were dividend yield 0% , fair value of common stock ranging from $5.00 to $ 6.10 , volatility of 56% , risk-free interest rate ranging from 1.01% to 1.23% , and a contractual life of five years . The fair value of the warrants was recorded as a warrant liability. The estimated value, which represents issuance costs, is recorded to additional paid in capital. The warrants expire 5 years from the issuance date. Total outstanding warrants as of September 30, 2016 are as follows: Number of Warrants Exercise Price Fair Value at date of issuance Equity classified November 2010 warrants issued with Series C convertible preferred stock 12,117 $ 21.64 $ 212,409 January 2011 warrants issued with Series C convertible preferred stock 19,042 21.64 259,355 December 2011 warrants issued with Series A convertible preferred stock 1,109 13.53 6,930 June 2013 warrants issued in conjunction with note purchase agreement 9,241 21.64 152,750 April 2014 warrants issued in conjunction with drawdown on note purchase agreement 9,242 21.64 149,250 August 2015 warrants issued with refinance of note purchase agreement 16,173 21.64 234,719 Liability classified June to August 2016 warrants issued with in conjunction with merger 17,504 5.00 44,663 Total outstanding warrants 84,428 For the nine month period ended September 30, 2016 and 2015 , respectively, $436,814 and $92,596 were recorded to other income from the revaluation of the warrants to fair market value. In June 2016, in connection with the Merger, 66,924 of the outstanding warrants valued at $53,436 were reclassified from warrant liability to additional paid-in capital in the accompanying consolidated balance sheets. The following assumptions were used in the Black-Scholes model to value the outstanding warrants: Nine Months Ended September 30, 2016 Year Ended December 31, 2015 Expected term (years) 4.68 - 4.85 .94 - 9.60 Expected volatility 53% 57% Risk-free interest rate 1.14% .65% - 2.27% Annual dividend rate —% —% Stock Price $6.10 $11.50- $22.05

Convertible Preferred Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock In June 2016, upon the closing of the Merger, all of the Company’s outstanding preferred stock of 3,564,629 shares was converted into 3,611,857 shares of common stock and the authorized preferred stock was decreased to 5,000,000 shares of “blank check” preferred stock, par value of $0.001 per share. Convertible preferred stock at December 31, 2015 consisted of the following: Series Shares Authorized Shares Issued and Outstanding Per Share Liquidation Preference Aggregate Liquidation Amount Carrying Value Series A 2,100,000 147,864 $ 13.53 $ 2,000,000 $ 1,966,935 Series B 9,000,000 589,784 24.35 14,359,244 14,261,779 Series C 23,000,000 1,625,203 21.64 35,171,735 35,171,735 Series D 17,000,000 1,201,778 21.64 26,008,207 26,008,207 51,100,000 3,564,629 $ 77,539,186 $ 77,408,656

Stock Warrants

Stock Warrants	9 Months Ended
	Sep. 30, 2016
Warrants and Rights Note Disclosure [Abstract]
Stock Warrants	Common Stock The Company’s amended Articles of Incorporation authorize the Company to issue 100,000,000 shares of $0.001 common stock. The common stockholders are entitled to elect three members to the Board. The holders of common stock are also entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board. As of September 30, 2016 , no dividends have been declared to date. In connection with the Merger, 1,568,726 shares of common stock were issued in exchange for cash proceeds, net of issuance costs, of $7,057,177 and 900,000 shares were issued to the shareholders of KTL Bamboo International Corp. At September 30, 2016 , the Company had reserved common stock for future issuance as follows: Exercise of options under stock plan 1,378,546 Issuance of options under stock plan 103,703 Exercise of common stock warrants 84,428 Common stock reserved for future issuance 1,566,677 Stock Warrants From June to August 2016, the Company issued warrants to purchase 17,504 shares of the common stock in conjunction with the Merger at an exercise price of $5.00 . The Company determined the value of the warrants on the date of issuance to be $44,663 using the Black-Scholes option pricing model. Assumptions used were dividend yield 0% , fair value of common stock ranging from $5.00 to $ 6.10 , volatility of 56% , risk-free interest rate ranging from 1.01% to 1.23% , and a contractual life of five years . The fair value of the warrants was recorded as a warrant liability. The estimated value, which represents issuance costs, is recorded to additional paid in capital. The warrants expire 5 years from the issuance date. Total outstanding warrants as of September 30, 2016 are as follows: Number of Warrants Exercise Price Fair Value at date of issuance Equity classified November 2010 warrants issued with Series C convertible preferred stock 12,117 $ 21.64 $ 212,409 January 2011 warrants issued with Series C convertible preferred stock 19,042 21.64 259,355 December 2011 warrants issued with Series A convertible preferred stock 1,109 13.53 6,930 June 2013 warrants issued in conjunction with note purchase agreement 9,241 21.64 152,750 April 2014 warrants issued in conjunction with drawdown on note purchase agreement 9,242 21.64 149,250 August 2015 warrants issued with refinance of note purchase agreement 16,173 21.64 234,719 Liability classified June to August 2016 warrants issued with in conjunction with merger 17,504 5.00 44,663 Total outstanding warrants 84,428 For the nine month period ended September 30, 2016 and 2015 , respectively, $436,814 and $92,596 were recorded to other income from the revaluation of the warrants to fair market value. In June 2016, in connection with the Merger, 66,924 of the outstanding warrants valued at $53,436 were reclassified from warrant liability to additional paid-in capital in the accompanying consolidated balance sheets. The following assumptions were used in the Black-Scholes model to value the outstanding warrants: Nine Months Ended September 30, 2016 Year Ended December 31, 2015 Expected term (years) 4.68 - 4.85 .94 - 9.60 Expected volatility 53% 57% Risk-free interest rate 1.14% .65% - 2.27% Annual dividend rate —% —% Stock Price $6.10 $11.50- $22.05

Stock Option Plan

Stock Option Plan	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Plan	Stock Option Plan In June 2016, the Board approved repricing of outstanding stock options to current employee and consultant option holders. In exchange for extending the vesting of options for an additional six months , the price of the outstanding stock grants was amended to $5.00 per share. The offer expired on July 12, 2016. Outstanding option shares of 744,133 , ranging in grant prices from $6.36 to $8.66 , were approved by the Board on July 14, 2016 and were repriced as part of the program. The expense related to the repricing during the quarter ended September 30, 2016 was $173,512 . The following table summarizes activity under the 2006 Stock Option Plan (the “ Plan ”) for the nine month period ended September 30, 2016 and year ended December 31, 2015 : Outstanding Options Shares Available for Grant Number of Options Weighted Average Exercise Price Balance, December 31, 2014 66,354 629,559 $ 6.49 Additional shares reserved 221,797 Options granted (271,414 ) 271,414 7.57 Options exercised (13,246 ) 3.92 Options forfeited 31,823 (31,823 ) 7.17 Balance, December 31, 2015 48,560 855,904 $ 6.76 Additional shares reserved 599,535 Options granted (563,810 ) 563,810 5.63 Options exercised (21,750 ) 2.28 Options forfeited 19,418 (19,418 ) 7.38 Balance, September 30, 2016 103,703 1,378,546 $ 5.21 The following table summarizes information about stock options outstanding at September 30, 2016 : Options Outstanding Options Vested Exercise Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Aggregate Intrinsic Value Number Vested Weighted Average Exercise Price Aggregate Intrinsic Value $ 1.3600 14,856 1.16 $ 1.3600 $ 70,417 14,856 $ 1.3600 $ 70,417 2.4400 8,501 1.55 2.4400 31,114 8,501 2.4400 31,114 4.3300 29,553 3.35 4.3300 52,309 29,553 4.3300 52,309 5.0000 743,736 7.57 5.0000 818,110 355,652 5.0000 391,217 5.5700 433,615 9.90 5.5700 229,816 63,209 5.5700 33,501 5.5925 112,651 9.90 5.5925 57,170 2,345 5.5925 1,190 6.3600 20,248 2.12 6.3600 — 20,248 6.3600 — 6.6300 2,290 7.79 6.6300 — 2,290 6.6300 — 7.4400 8,166 5.35 7.4400 — 8,166 7.4400 — 7.5800 1,289 8.79 7.5800 — 1,289 7.5800 — 8.6600 3,641 6.43 8.6600 — 3,641 8.6600 — 1,378,546 8.20 $ 5.2100 $ 1,258,936 509,750 $ 5.0200 $ 579,748 Stock-Based Compensation Associated with Awards to Employees During the nine month period ended September 30, 2016 , the Company granted stock options to employees to purchase 563,810 shares of common stock with a weighted-average grant date fair value of $5.63 . Stock-based employee compensation expense recognized during the nine -month periods ended September 30, 2016 and 2015 was $748,807 and $425,303 , respectively. As of September 30, 2016 , there were total unrecognized compensation costs of $1,607,851 related to these stock options. These costs are expected to be recognized over a period of approximately 2.59 years. The total fair value of employee options vested during the nine -month periods ended September 30, 2016 and 2015 was $666,843 and $587,843 , respectively. The Company estimated the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Nine months ended September 30, 2016 Year ended December 31, 2015 Expected term (in years) 5.22 years 5.65 years Expected volatility 46% 49% Risk-free interest rate 1.17%-1.54% 1.43% -1.74% Dividend yield —% —% Stock-Based Compensation Associated with Awards to Non-employees In April 2015, the Company granted stock options to a board advisor to purchase 99,312 shares of common stock at $7.57 . In July 2016, these shares were repriced to $5.00 . In August 2016, the Company granted stock options to purchase an additional 40,608 shares of common stock at $5.57 to a board advisor and 112,651 shares of common stock at $5.5925 to the Company’s Board of Directors. Stock-based compensation expense recognized during the nine -month periods ended September 30, 2016 and 2015 was $104,866 and $39,489 , respectively. As of September 30, 2016 , there was total unrecognized compensation costs of $580,947 related to these stock options. These costs are expected to be recognized over a period of approximately 3.29 years. The fair value of the stock options granted to non-employees is calculated at each reporting date using the Black-Scholes options pricing model. The fair value of stock options granted to non-employees was estimated using the following weighted average assumptions: Nine months ended September 30, 2016 Year ended December 31, 2015 Expected term (in years) 5.97 years 5.67 years Expected volatility 47% 49% Risk-free interest rate 1.29% -1.35% 1.43% Dividend yield —% —%

Employee Benefit Plan

Employee Benefit Plan	9 Months Ended
	Sep. 30, 2016
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Employee Benefit Plan The Company sponsors a 401(k) plan covering all employees. Contributions made by the Company are discretionary and are determined annually by the Board. The Company accrues for a 100% match for employee contributions up to $1,000 . As of September 30, 2016 and December 31, 2015 , the Company had accrued $41,496 and $48,183 , respectively, for employer contributions.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share The Company’s basic and diluted net loss per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net loss $ (3,921,958 ) $ (3,667,206 ) $ (17,004,551 ) $ (11,693,609 ) Accretion of redeemable convertible preferred stock — (20,000 ) — (63,117 ) Net loss attributable to common stockholders (3,921,958 ) (3,687,206 ) (17,004,551 ) (11,756,726 ) Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted 9,256,362 385,271 4,030,810 385,271 Net loss per share attributable to common stockholders, basic and diluted $ (0.42 ) $ (9.57 ) $ (4.22 ) $ (30.52 ) The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Convertible preferred stock (if converted) — 3,611,857 — 3,611,857 Stock warrants 84,428 66,924 84,428 66,924 Options to purchase common stock 1,378,546 873,107 1,378,546 873,107

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Management has evaluated all transactions and events through November 9, 2016 , the date on which these financial statements were issued, and did not note any items that would adjust the financial statements or require additional disclosures.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Intercompany balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s most significant estimates relate to inventory valuation and reserves, warranty accruals, deferred tax asset valuation allowance and valuation of equity and equity-linked instruments (common stock, options and warrants). Our management believes that we consistently apply these judgments and estimates and the consolidated financial statements and accompanying notes fairly represent all periods presented. However, any differences between these judgments and estimates and actual results could have a material impact on our consolidated statements of income and financial position.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents are deposited with one financial institution in the United States of America. Deposits in this institution may exceed the amount of insurance provided on such deposits.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There were no changes to the new accounts pronouncements as described in the Company’s financial statements for the year ended December 31, 2015, filed on Form 8-K on June 13, 2016, except for the following: In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments .” This update provides guidance on the required presentation and classification in the statement of cash flows for various issues for which there has been diversity in practice in the past. For public entities, the new standard is effective for annual periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company is currently evaluating the effect that the standard will have on the consolidated financial statements.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Schedule of Customer Concentration of Accounts Receivable and Revenue	The Company’s customers representing greater than 10% of accounts receivable and revenue were as follows: Revenue Accounts Receivable Nine Months Ended September 30, September 30, December 31, 2016 2015 2016 2015 Customer A 12% * * * Customer B * * 28% * Customer C * * 11% 12% Customer D * 15% * 20% Customer E * * * 23%

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventories	Inventories September 30, 2016 December 31, 2015 (Unaudited) Raw materials $ 2,365,170 $ 2,132,655 Work in progress 1,960,245 1,263,019 Finished goods 1,287,730 1,396,067 $ 5,613,145 $ 4,791,741
Schedule of Property and Equipment, Net	Property and Equipment, Net September 30, 2016 December 31, 2015 (Unaudited) Leasehold Improvements $ 844,360 $ 844,360 Machinery and equipment 1,508,074 1,355,986 Computer and office equipment 241,291 241,291 Software 326,992 326,992 Furniture and fixtures 114,564 114,564 Leased equipment — 168,143 3,035,281 3,051,336 Less: Accumulated depreciation and amortization (2,251,339 ) (1,840,207 ) $ 783,942 $ 1,211,129
Schedule of Accrued Liabilities	Accrued Liabilities September 30, 2016 December 31, 2015 (Unaudited) Accrued payroll and related expenses $ 1,795,317 $ 1,457,534 Accrued royalty 1,740,520 1,226,973 Accrued warranty 181,000 217,000 Accrued marketing 286,620 165,600 Accrued clinical expenses 11,500 2,600 Accrued legal 67,200 112,000 Capital lease payable, current 21,814 33,909 Deferred rent, current 30,705 18,672 Accrued other expenses 378,642 338,153 $ 4,513,318 $ 3,572,441
Schedule of Accrued Product Warranty	The warranty accrual as of September 30, 2016 and December 31, 2015 consisted of the following activity: Warranty accrual, December 31, 2014 $ 253,000 Accruals for product warranty 427,467 Cost of warranty claims (463,467 ) Warranty accrual, December 31, 2015 $ 217,000 Accruals for product warranty 303,738 Cost of warranty claims (339,738 ) Warranty accrual, September 30, 2016 $ 181,000

Fair Value of Financial Instr25

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Financial Assets and Liabilities Measured on a Recurring Basis	The fair value of the Company’s financial assets and liabilities measured on a recurring basis, as of September 30, 2016 and December 31, 2015 , were as follows: September 30, 2016 Level 1 Level 2 Level 3 Total Liabilities Warrant liability $ — $ — $ 54,029 $ 54,029 December 31, 2015 Level 1 Level 2 Level 3 Total Liabilities Warrant liability $ — $ — $ 499,616 $ 499,616
Changes in the Convertible Preferred Stock Warrant Liability	The changes in the warrant liability are summarized below: Fair value at December 31, 2014 $ 371,039 Fair value of warrants issued during the year 234,719 Change in fair value recorded in interest and other income, net (106,142 ) Fair value at December 31, 2015 $ 499,616 Fair value of warrants issued during the year 44,663 Conversion to common stock warrants (53,436 ) Change in fair value recorded in interest and other income, net (436,814 ) Fair value at September 30, 2016 $ 54,029

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Aggregate Future Minimum Operating Lease Payments	The aggregate future minimum lease payments under all leases are as follows: Operating Lease Capital Leases Three months ended December 31, 2016 $ 135,014 $ 5,256 Year ending December 31, 2017 552,207 17,249 Year ending December 31, 2018 568,773 — Year ending December 31, 2019 241,592 — Total minimum lease payments $ 1,497,586 22,505 Less: Amount representing interest (691 ) Present value of minimum lease payments 21,814 Less: current portion of capital leases (21,814 ) Long term portion of capital leases $ —
Schedule of Aggregate Future Minimum Capital Lease Payments	The aggregate future minimum lease payments under all leases are as follows: Operating Lease Capital Leases Three months ended December 31, 2016 $ 135,014 $ 5,256 Year ending December 31, 2017 552,207 17,249 Year ending December 31, 2018 568,773 — Year ending December 31, 2019 241,592 — Total minimum lease payments $ 1,497,586 22,505 Less: Amount representing interest (691 ) Present value of minimum lease payments 21,814 Less: current portion of capital leases (21,814 ) Long term portion of capital leases $ —

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Annual Future Principal Payments Under Notes Payable	Annual future principal payments under the notes payable are as follows: Three months ended December 31, 2016 $ 131,293 Year ending December 31, 2017 3,477,349 Year ending December 31, 2018 3,665,814 Year ending December 31, 2019 2,942,582 Total payments 10,217,038 Less: Unamortized debt discount (277,777 ) Carrying value of notes payable $ 9,939,261

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Schedule of Reserved Common Stock	At September 30, 2016 , the Company had reserved common stock for future issuance as follows: Exercise of options under stock plan 1,378,546 Issuance of options under stock plan 103,703 Exercise of common stock warrants 84,428 Common stock reserved for future issuance 1,566,677

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Schedule of Convertible Preferred Stock	Convertible preferred stock at December 31, 2015 consisted of the following: Series Shares Authorized Shares Issued and Outstanding Per Share Liquidation Preference Aggregate Liquidation Amount Carrying Value Series A 2,100,000 147,864 $ 13.53 $ 2,000,000 $ 1,966,935 Series B 9,000,000 589,784 24.35 14,359,244 14,261,779 Series C 23,000,000 1,625,203 21.64 35,171,735 35,171,735 Series D 17,000,000 1,201,778 21.64 26,008,207 26,008,207 51,100,000 3,564,629 $ 77,539,186 $ 77,408,656

Stock Warrants (Tables)

Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2016
Warrants and Rights Note Disclosure [Abstract]
Schedule of Options Outstanding	Total outstanding warrants as of September 30, 2016 are as follows: Number of Warrants Exercise Price Fair Value at date of issuance Equity classified November 2010 warrants issued with Series C convertible preferred stock 12,117 $ 21.64 $ 212,409 January 2011 warrants issued with Series C convertible preferred stock 19,042 21.64 259,355 December 2011 warrants issued with Series A convertible preferred stock 1,109 13.53 6,930 June 2013 warrants issued in conjunction with note purchase agreement 9,241 21.64 152,750 April 2014 warrants issued in conjunction with drawdown on note purchase agreement 9,242 21.64 149,250 August 2015 warrants issued with refinance of note purchase agreement 16,173 21.64 234,719 Liability classified June to August 2016 warrants issued with in conjunction with merger 17,504 5.00 44,663 Total outstanding warrants 84,428
Schedule of Stock Option Plan Fair Value Valuation Assumptions	The following assumptions were used in the Black-Scholes model to value the outstanding warrants: Nine Months Ended September 30, 2016 Year Ended December 31, 2015 Expected term (years) 4.68 - 4.85 .94 - 9.60 Expected volatility 53% 57% Risk-free interest rate 1.14% .65% - 2.27% Annual dividend rate —% —% Stock Price $6.10 $11.50- $22.05

Stock Option Plan (Tables)

Stock Option Plan (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Option Plan Summary Activity	The following table summarizes activity under the 2006 Stock Option Plan (the “ Plan ”) for the nine month period ended September 30, 2016 and year ended December 31, 2015 : Outstanding Options Shares Available for Grant Number of Options Weighted Average Exercise Price Balance, December 31, 2014 66,354 629,559 $ 6.49 Additional shares reserved 221,797 Options granted (271,414 ) 271,414 7.57 Options exercised (13,246 ) 3.92 Options forfeited 31,823 (31,823 ) 7.17 Balance, December 31, 2015 48,560 855,904 $ 6.76 Additional shares reserved 599,535 Options granted (563,810 ) 563,810 5.63 Options exercised (21,750 ) 2.28 Options forfeited 19,418 (19,418 ) 7.38 Balance, September 30, 2016 103,703 1,378,546 $ 5.21
Schedule of Stock Option Plan Options Outstanding	The following table summarizes information about stock options outstanding at September 30, 2016 : Options Outstanding Options Vested Exercise Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Aggregate Intrinsic Value Number Vested Weighted Average Exercise Price Aggregate Intrinsic Value $ 1.3600 14,856 1.16 $ 1.3600 $ 70,417 14,856 $ 1.3600 $ 70,417 2.4400 8,501 1.55 2.4400 31,114 8,501 2.4400 31,114 4.3300 29,553 3.35 4.3300 52,309 29,553 4.3300 52,309 5.0000 743,736 7.57 5.0000 818,110 355,652 5.0000 391,217 5.5700 433,615 9.90 5.5700 229,816 63,209 5.5700 33,501 5.5925 112,651 9.90 5.5925 57,170 2,345 5.5925 1,190 6.3600 20,248 2.12 6.3600 — 20,248 6.3600 — 6.6300 2,290 7.79 6.6300 — 2,290 6.6300 — 7.4400 8,166 5.35 7.4400 — 8,166 7.4400 — 7.5800 1,289 8.79 7.5800 — 1,289 7.5800 — 8.6600 3,641 6.43 8.6600 — 3,641 8.6600 — 1,378,546 8.20 $ 5.2100 $ 1,258,936 509,750 $ 5.0200 $ 579,748
Schedule of Stock Option Plan Fair Value Valuation Assumptions	The fair value of employee stock options granted was estimated using the following weighted average assumptions: Nine months ended September 30, 2016 Year ended December 31, 2015 Expected term (in years) 5.22 years 5.65 years Expected volatility 46% 49% Risk-free interest rate 1.17%-1.54% 1.43% -1.74% Dividend yield —% —%
Schedule of Stock Option Plan Fair Value Valuation Assumptions, Non-Employees	The fair value of stock options granted to non-employees was estimated using the following weighted average assumptions: Nine months ended September 30, 2016 Year ended December 31, 2015 Expected term (in years) 5.97 years 5.67 years Expected volatility 47% 49% Risk-free interest rate 1.29% -1.35% 1.43% Dividend yield —% —%

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The Company’s basic and diluted net loss per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net loss $ (3,921,958 ) $ (3,667,206 ) $ (17,004,551 ) $ (11,693,609 ) Accretion of redeemable convertible preferred stock — (20,000 ) — (63,117 ) Net loss attributable to common stockholders (3,921,958 ) (3,687,206 ) (17,004,551 ) (11,756,726 ) Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted 9,256,362 385,271 4,030,810 385,271 Net loss per share attributable to common stockholders, basic and diluted $ (0.42 ) $ (9.57 ) $ (4.22 ) $ (30.52 )
Schedule of Weighted-average Common Stock Equivalents Excluded From Calculation of Diluted Net Loss Per Share	The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Convertible preferred stock (if converted) — 3,611,857 — 3,611,857 Stock warrants 84,428 66,924 84,428 66,924 Options to purchase common stock 1,378,546 873,107 1,378,546 873,107

Background and Organization (De

Background and Organization (Details)	Jun. 07, 2016	Sep. 30, 2016USD ($)	Dec. 31, 2015USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stock conversion ratio	13.5263
Accumulated deficit		$ 110,451,679	$ 93,447,128

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Accounting Policies [Abstract]
Uninsured cash balances	$ 6,101,499
Customer concentration risk | Revenue | Customer A
Concentration Risk [Line Items]
Concentration percentage	12.00%
Customer concentration risk | Revenue | Customer D
Concentration Risk [Line Items]
Concentration percentage		15.00%
Customer concentration risk | Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration percentage	28.00%
Customer concentration risk | Accounts Receivable | Customer C
Concentration Risk [Line Items]
Concentration percentage	11.00%		12.00%
Customer concentration risk | Accounts Receivable | Customer D
Concentration Risk [Line Items]
Concentration percentage			20.00%
Customer concentration risk | Accounts Receivable | Customer E
Concentration Risk [Line Items]
Concentration percentage			23.00%
Geographic concentration risk | Revenue | North America
Concentration Risk [Line Items]
Concentration percentage	46.00%	44.00%

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory, Raw Materials, Net of Reserves	$ 2,365,170	$ 2,132,655
Inventory, Work in Process, Net of Reserves	1,960,245	1,263,019
Inventory, Finished Goods, Net of Reserves	1,287,730	1,396,067
Inventories	$ 5,613,145	$ 4,791,741

Balance Sheet Components - Sc36

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,035,281	$ 3,051,336
Less: Accumulated depreciation and amortization	(2,251,339)	(1,840,207)
Property and equipment, net	783,942	1,211,129
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	844,360	844,360
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,508,074	1,355,986
Computer and office equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	241,291	241,291
Software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	326,992	326,992
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	114,564	114,564
Leased equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 0	$ 168,143

Balance Sheet Components - Narr

Balance Sheet Components - Narrative (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation and amortization	$ 411,132	$ 526,904

Balance Sheet Components - Accr

Balance Sheet Components - Accrued Liabilities (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related expenses	$ 1,795,317	$ 1,457,534
Accrued royalty	1,740,520	1,226,973
Accrued warranty	181,000	217,000
Accrued marketing	286,620	165,600
Accrued clinical expenses	11,500	2,600
Accrued legal	67,200	112,000
Capital lease payable, current	21,814	33,909
Deferred rent, current	30,705	18,672
Accrued other expenses	378,642	338,153
Accrued liabilities	$ 4,513,318	$ 3,572,441

Balance Sheet Components - Ac39

Balance Sheet Components - Accrued Warranty (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Warranty accrual activity
Warranty accrual, beginning of period	$ 217,000	$ 253,000
Accruals for product warranty	303,738	427,467
Cost of warranty claims	(339,738)	(463,467)
Warranty accrual, end of period	$ 181,000	$ 217,000

Fair Value of Financial Instr40

Fair Value of Financial Instruments - Assets and Liabilities Measured on a Recurring Basis (Details) - Stock warrants - Fair Value, Measurements, Recurring - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Liabilities
Warrant liability	$ 54,029	$ 499,616
Level 1
Liabilities
Warrant liability	0	0
Level 2
Liabilities
Warrant liability	0	0
Level 3
Liabilities
Warrant liability	$ 54,029	$ 499,616

Fair Value of Financial Instr41

Fair Value of Financial Instruments - Changes in Warrant Liability (Details) - Stock warrants - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Changes in the warrant liability
Beginning balance	$ 499,616	$ 371,039
Fair value of warrants issued during the year	44,663	234,719
Conversion to common stock warrants	(53,436)
Change in fair value recorded in interest and other income, net	(436,814)	(106,142)
Ending balance	$ 54,029	$ 499,616

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2013	Feb. 29, 2008	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Accrued royalty			$ 1,740,520		$ 1,226,973
The Foundry | Seed capital and management services
Related Party Transaction [Line Items]
Total amount reimbursed for services			46,976	$ 47,051
The Foundry | Royalty agreements
Related Party Transaction [Line Items]
Agreement rate (percent)	3.00%	1.50%
Maximum royalties		$ 30,000,000
Accrued royalty			1,740,520		1,226,973
Royalties paid			$ 0		$ 0
The Foundry | Royalty agreements | Prime rate
Related Party Transaction [Line Items]
Spread on prime rate (percent)			1.00%
The Foundry | Licensed products
Related Party Transaction [Line Items]
Agreement rate (percent)		1.50%
The Foundry | Patented products
Related Party Transaction [Line Items]
Agreement rate (percent)		1.50%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Loss Contingencies [Line Items]
Rent expense under the company's operating leases	$ 429,685	$ 424,912
Indemnification agreement | Directors
Loss Contingencies [Line Items]
Liability associated with indemnification	0		$ 0
Defects in device
Loss Contingencies [Line Items]
Liability associated with indemnification	$ 0		$ 0

Commitments and Contingencies44

Commitments and Contingencies - Future Minimum Lease Payments (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Operating Lease
Three months ended December 31, 2016	$ 135,014
Year ending December 31, 2017	552,207
Year ending December 31, 2018	568,773
Year ending December 31, 2019	241,592
Total minimum lease payments	1,497,586
Capital Leases
Three months ended December 31, 2016	5,256
Year ending December 31, 2017	17,249
Year ending December 31, 2018	0
Year ending December 31, 2019	0
Total minimum lease payments	22,505
Less: Amount representing interest	(691)
Present value of minimum lease payments	21,814
Less: current portion of capital leases	(21,814)	$ (33,909)
Long term portion of capital leases	$ 0	$ 16,865

Notes Payable - Narrative (Deta

Notes Payable - Narrative (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Jun. 30, 2016	Feb. 29, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	May 31, 2016	Dec. 31, 2015	Aug. 31, 2015	Jun. 30, 2013
Debt Instrument [Line Items]
Loss on debt conversion			$ 0	$ 0	$ 8,062,001	$ 0
Common Stock
Debt Instrument [Line Items]
Conversion of outstanding notes (shares)	2,828,469
Insurance premiums financing agreements
Debt Instrument [Line Items]
Payment term					9 months
Outstanding balance of financing agreements			$ 217,038		$ 217,038			$ 40,889
Insurance premiums financing agreements | Minimum
Debt Instrument [Line Items]
Interest rate (percent)			2.25%		2.25%
Insurance premiums financing agreements | Maximum
Debt Instrument [Line Items]
Interest rate (percent)			4.95%		4.95%
December 2015 Note Purchase Agreement | Convertible promissory notes
Debt Instrument [Line Items]
Maximum amount								1,500,000
December 2015 Notes | Convertible promissory notes
Debt Instrument [Line Items]
Aggregate principal amount		$ 1,300,000						$ 1,300,000
February 2016 Notes | Convertible promissory notes
Debt Instrument [Line Items]
Aggregate principal amount		2,700,000
Maximum amount		$ 2,700,000					$ 4,850,000
Interest rate (percent)		8.00%
Payment term		1 year
February 2016 Notes | Convertible promissory notes | Series D
Debt Instrument [Line Items]
Conversion price (usd per share)		$ 21.64
May 2016 Notes | Convertible promissory notes
Debt Instrument [Line Items]
Aggregate principal amount							$ 2,000,000
Outstanding notes	$ 6,000,000
Loss on debt conversion	$ 8,062,001
Secured promissory notes | August 2015 Secured Promissory Notes
Debt Instrument [Line Items]
Aggregate principal amount										$ 10,000,000
Interest rate (percent)									7.80%
Secured promissory notes | June 2013 Secured Promissory Notes
Debt Instrument [Line Items]
Maximum amount									$ 20,000,000
Secured promissory notes | June 2013 Secured Promissory Note - Tranche 1
Debt Instrument [Line Items]
Maximum amount									5,000,000
Secured promissory notes | June 2013 Secured Promissory Note - Tranche 2
Debt Instrument [Line Items]
Maximum amount									$ 5,000,000

Notes Payable - Schedule of Ann

Notes Payable - Schedule of Annual Future Principal Payments Under Notes Payable (Details)	Sep. 30, 2016USD ($)
Debt Disclosure [Abstract]
Three months ended December 31, 2016	$ 131,293
Year ending December 31, 2017	3,477,349
Year ending December 31, 2018	3,665,814
Year ending December 31, 2019	2,942,582
Total payments	10,217,038
Less: Unamortized debt discount	(277,777)
Carrying value of notes payable	$ 9,939,261

Common Stock - Additional Infor

Common Stock - Additional Information (Details)	Jun. 07, 2016USD ($)shares	Sep. 30, 2016USD ($)board_member$ / sharesshares	Dec. 31, 2015$ / sharesshares
Equity [Abstract]
Common stock, shares issued (shares)		100,000,000	105,500,000
Common stock, par value (usd per share) | $ / shares		$ 0.001	$ 0.001
Number of board members that common stockholders are entitled to elect | board_member		3
Shares of common stock sold (shares)	1,568,726
Net proceeds from issuance of common stock | $	$ 7,057,177	$ 7,057,177
Issuance of common stock (shares)	900,000

Common Stock - Reserved for Iss

Common Stock - Reserved for Issuance (Details)	Sep. 30, 2016shares
Equity [Abstract]
Exercise of options under stock plan (shares)	1,378,546
Issuance of options under stock plan (shares)	103,703
Exercise of common stock warrants (shares)	84,428
Common stock reserved for future issuance (shares)	1,566,677

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Details) - $ / shares	1 Months Ended	9 Months Ended
	Jun. 30, 2016	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Outstanding preferred stock (shares)	3,564,629
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (shares)	5,000,000
Par value of preferred stock (usd per share)	$ 0.001
Common Stock
Class of Stock [Line Items]
Conversion of preferred stock to common stock in connection with the merger (shares)	3,611,857	3,611,857

Convertible Preferred Stock - S

Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (shares)		5,000,000
Redeemable convertible preferred stock, shares authorized (shares)	0		40,000,000
Total Shares Authorized			51,100,000
Redeemable convertible preferred stock, shares issued (shares)			2,826,981
Total Shares Issued		3,564,629
Redeemable convertible preferred stock, shares outstanding (shares)	0		2,826,981	2,826,981
Total Shares Outstanding			3,564,629
Redeemable convertible preferred stock, liquidation preference			$ 61,179,942
Total Aggregate Liquidation Amount			77,539,186
Redeemable convertible preferred stock, carrying value	$ 0		61,179,942	$ 61,179,942
Total Carrying Value			$ 77,408,656
Series A
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (shares)	0		2,100,000
Convertible preferred stock, shares issued (shares)			147,864
Convertible preferred stock, shares outstanding (shares)	0		147,864
Convertible preferred stock, Per Share Liquidation Preference (usd per share)			$ 13.53
Convertible preferred stock, liquidation preference			$ 2,000,000
Convertible preferred stock, carrying value			$ 1,966,935
Series B
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (shares)	0		9,000,000
Convertible preferred stock, shares issued (shares)			589,784
Convertible preferred stock, shares outstanding (shares)	0		589,784
Convertible preferred stock, Per Share Liquidation Preference (usd per share)			$ 24.35
Convertible preferred stock, liquidation preference			$ 14,359,244
Convertible preferred stock, carrying value			$ 14,261,779
Series C
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized (shares)			23,000,000
Redeemable convertible preferred stock, shares issued (shares)			1,625,203
Redeemable convertible preferred stock, shares outstanding (shares)			1,625,203
Redeemable convertible preferred stock, Per Share Liquidation Preference (usd per share)			$ 21.64
Redeemable convertible preferred stock, liquidation preference			$ 35,171,735
Redeemable convertible preferred stock, carrying value			$ 35,171,735
Series D
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized (shares)			17,000,000
Redeemable convertible preferred stock, shares issued (shares)			1,201,778
Redeemable convertible preferred stock, shares outstanding (shares)			1,201,778
Redeemable convertible preferred stock, Per Share Liquidation Preference (usd per share)			$ 21.64
Redeemable convertible preferred stock, liquidation preference			$ 26,008,207
Redeemable convertible preferred stock, carrying value			$ 26,008,207

Stock Warrants - Additional Inf

Stock Warrants - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Aug. 31, 2016	Sep. 30, 2016	Sep. 30, 2015
Class of Warrant or Right [Line Items]
Revaluation of warrants to fair market value		$ 436,814	$ 92,596
Number of Warrants (shares)		84,428
June to August 2016 warrants issued with in conjunction with merger
Class of Warrant or Right [Line Items]
Number of stock to be purchased by issued warrants (shares)	17,504
Exercise price (usd per share)	$ 5	$ 5
Fair value of issued warrants	$ 44,663	$ 44,663
Assumed dividend rate (percent)	0.00%
Assumed volatility rate (percent)	56.00%
Expected term (years)	5 years
Warrants expiration period	5 years
Number of Warrants (shares)		17,504
Minimum | June to August 2016 warrants issued with in conjunction with merger
Class of Warrant or Right [Line Items]
Share price (usd per share)	$ 5
Assumed risk free rate (percent)	1.01%
Maximum | June to August 2016 warrants issued with in conjunction with merger
Class of Warrant or Right [Line Items]
Share price (usd per share)	$ 6.10
Assumed risk free rate (percent)	1.23%
Additional Paid-In Capital | June 2016 warrants issued with in conjunction with merger
Class of Warrant or Right [Line Items]
Fair value of issued warrants		$ 53,436
Number of Warrants (shares)		66,924

Stock Warrants - Schedule of Ou

Stock Warrants - Schedule of Outstanding Warrants (Details) - USD ($)	Sep. 30, 2016	Aug. 31, 2016
Class of Warrant or Right [Line Items]
Number of Warrants (shares)	84,428
November 2010 warrants issued with Series C convertible preferred stock
Class of Warrant or Right [Line Items]
Number of Warrants (shares)	12,117
Exercise price (usd per share)	$ 21.64
Fair Value at date of issuance	$ 212,409
January 2011 warrants issued with Series C convertible preferred stock
Class of Warrant or Right [Line Items]
Number of Warrants (shares)	19,042
Exercise price (usd per share)	$ 21.64
Fair Value at date of issuance	$ 259,355
December 2011 warrants issued with Series A convertible preferred stock
Class of Warrant or Right [Line Items]
Number of Warrants (shares)	1,109
Exercise price (usd per share)	$ 13.53
Fair Value at date of issuance	$ 6,930
June 2013 warrants issued in conjunction with note purchase agreement
Class of Warrant or Right [Line Items]
Number of Warrants (shares)	9,241
Exercise price (usd per share)	$ 21.64
Fair Value at date of issuance	$ 152,750
April 2014 warrants issued in conjunction with drawdown on note purchase agreement
Class of Warrant or Right [Line Items]
Number of Warrants (shares)	9,242
Exercise price (usd per share)	$ 21.64
Fair Value at date of issuance	$ 149,250
August 2015 warrants issued with refinance of note purchase agreement
Class of Warrant or Right [Line Items]
Number of Warrants (shares)	16,173
Exercise price (usd per share)	$ 21.64
Fair Value at date of issuance	$ 234,719
June to August 2016 warrants issued with in conjunction with merger
Class of Warrant or Right [Line Items]
Number of Warrants (shares)	17,504
Exercise price (usd per share)	$ 5	$ 5
Fair Value at date of issuance	$ 44,663	$ 44,663

Stock Warrants - Schedule of St

Stock Warrants - Schedule of Stock Option Plan Fair Value Valuation Assumptions (Details) - Stock warrants - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Assumed volatility rate (percent)	53.00%	57.00%
Assumed risk free rate (percent)	1.14%
Assumed dividend rate (percent)	0.00%	0.00%
Share price (usd per share)	$ 6.10
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term (years)	4 years 8 months 5 days	11 months 9 days
Assumed risk free rate (percent)		0.65%
Share price (usd per share)		$ 11.5
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term (years)	4 years 10 months 6 days	9 years 7 months 6 days
Assumed risk free rate (percent)		2.27%
Share price (usd per share)		$ 22.05

Stock Option Plan - Stock Optio

Stock Option Plan - Stock Option Plan Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 30, 2016	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extension of the vesting of options (period)	6 months
Exercise price after adjustment (usd per share)		$ 5
Exercise price $6.36 - $8.66
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number outstanding (shares)		744,133
Exercise price, lower limit (usd per share)	$ 6.36
Exercise price, upper limit (usd per share)	$ 8.66
Repricing expense		$ 173,512

Stock Option Plan - Schedule of

Stock Option Plan - Schedule of Stock Option Plan Summary Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Weighted Average Exercise Price
Ending balance (usd per share)	$ 5
2006 Stock Option Plan
Shares Available for Grant
Beginning balance (shares)	48,560	66,354
Additional shares reserved (shares)	599,535	221,797
Options granted (shares)	(563,810)	(271,414)
Options forfeited (shares)	19,418	31,823
Beginning balance (shares)	103,703	48,560
Number of Options
Beginning balance (shares)	855,904	629,559
Options granted (shares)	563,810	271,414
Options exercised (shares)	(21,750)	(13,246)
Options forfeited (shares)	(19,418)	(31,823)
Ending balance (shares)	1,378,546	855,904
Weighted Average Exercise Price
Beginning balance (usd per share)	$ 6.76	$ 6.49
Options granted (usd per share)		7.57
Options granted (usd per share)	5.63
Options exercised (usd per share)	2.28	3.92
Options forfeited (usd per share)	7.38	7.17
Ending balance (usd per share)	$ 5.21	$ 6.76

Stock Option Plan - Schedule 56

Stock Option Plan - Schedule of Stock Option Plan Options Outstanding (Details) - 2006 Stock Option Plan	9 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Options Outstanding
Number outstanding (shares) | shares	1,378,546
Weighted Average Remaining Contractual Life	8 years 2 months 12 days
Weighted Average Exercise Price (usd per share)	$ 5.2100
Aggregate Intrinsic Value | $	$ 1,258,936
Options Vested
Number Vested (shares) | shares	509,750
Weighted Average Exercise Price (usd per share)	$ 5.0200
Aggregate Intrinsic Value | $	$ 579,748
Exercise price $1.36
Options Outstanding
Exercise price, lower limit (usd per share)	$ 1.3600
Exercise price, upper limit (usd per share)	$ 1.3600
Number outstanding (shares) | shares	14,856
Weighted Average Remaining Contractual Life	1 year 1 month 28 days
Weighted Average Exercise Price (usd per share)	$ 1.3600
Aggregate Intrinsic Value | $	$ 70,417
Options Vested
Number Vested (shares) | shares	14,856
Weighted Average Exercise Price (usd per share)	$ 1.3600
Aggregate Intrinsic Value | $	$ 70,417
Exercise price $2.44
Options Outstanding
Exercise price, lower limit (usd per share)	$ 2.4400
Exercise price, upper limit (usd per share)	$ 2.4400
Number outstanding (shares) | shares	8,501
Weighted Average Remaining Contractual Life	1 year 6 months 18 days
Weighted Average Exercise Price (usd per share)	$ 2.4400
Aggregate Intrinsic Value | $	$ 31,114
Options Vested
Number Vested (shares) | shares	8,501
Weighted Average Exercise Price (usd per share)	$ 2.4400
Aggregate Intrinsic Value | $	$ 31,114
Exercise price $4.33
Options Outstanding
Exercise price, lower limit (usd per share)	$ 4.3300
Exercise price, upper limit (usd per share)	$ 4.3300
Number outstanding (shares) | shares	29,553
Weighted Average Remaining Contractual Life	3 years 4 months 6 days
Weighted Average Exercise Price (usd per share)	$ 4.3300
Aggregate Intrinsic Value | $	$ 52,309
Options Vested
Number Vested (shares) | shares	29,553
Weighted Average Exercise Price (usd per share)	$ 4.3300
Aggregate Intrinsic Value | $	$ 52,309
Exercise price $5.00
Options Outstanding
Exercise price, lower limit (usd per share)	$ 5
Exercise price, upper limit (usd per share)	$ 5
Number outstanding (shares) | shares	743,736
Weighted Average Remaining Contractual Life	7 years 6 months 26 days
Weighted Average Exercise Price (usd per share)	$ 5
Aggregate Intrinsic Value | $	$ 818,110
Options Vested
Number Vested (shares) | shares	355,652
Weighted Average Exercise Price (usd per share)	$ 5
Aggregate Intrinsic Value | $	$ 391,217
Exercise price $5.57
Options Outstanding
Exercise price, lower limit (usd per share)	$ 5.5700
Exercise price, upper limit (usd per share)	$ 5.5700
Number outstanding (shares) | shares	433,615
Weighted Average Remaining Contractual Life	9 years 10 months 24 days
Weighted Average Exercise Price (usd per share)	$ 5.5700
Aggregate Intrinsic Value | $	$ 229,816
Options Vested
Number Vested (shares) | shares	63,209
Weighted Average Exercise Price (usd per share)	$ 5.5700
Aggregate Intrinsic Value | $	$ 33,501
Exercise price $5.9525
Options Outstanding
Exercise price, lower limit (usd per share)	$ 5.5925
Exercise price, upper limit (usd per share)	$ 5.5925
Number outstanding (shares) | shares	112,651
Weighted Average Remaining Contractual Life	9 years 10 months 24 days
Weighted Average Exercise Price (usd per share)	$ 5.5925
Aggregate Intrinsic Value | $	$ 57,170
Options Vested
Number Vested (shares) | shares	2,345
Weighted Average Exercise Price (usd per share)	$ 5.5925
Aggregate Intrinsic Value | $	$ 1,190
Exercise price $6.36
Options Outstanding
Exercise price, lower limit (usd per share)	$ 6.3600
Exercise price, upper limit (usd per share)	$ 6.3600
Number outstanding (shares) | shares	20,248
Weighted Average Remaining Contractual Life	2 years 1 month 13 days
Weighted Average Exercise Price (usd per share)	$ 6.3600
Aggregate Intrinsic Value | $	$ 0
Options Vested
Number Vested (shares) | shares	20,248
Weighted Average Exercise Price (usd per share)	$ 6.3600
Aggregate Intrinsic Value | $	$ 0
Exercise price $6.63
Options Outstanding
Exercise price, lower limit (usd per share)	$ 6.6300
Exercise price, upper limit (usd per share)	$ 6.6300
Number outstanding (shares) | shares	2,290
Weighted Average Remaining Contractual Life	7 years 9 months 15 days
Weighted Average Exercise Price (usd per share)	$ 6.6300
Aggregate Intrinsic Value | $	$ 0
Options Vested
Number Vested (shares) | shares	2,290
Weighted Average Exercise Price (usd per share)	$ 6.6300
Aggregate Intrinsic Value | $	$ 0
Exercise price $7.44
Options Outstanding
Exercise price, lower limit (usd per share)	$ 7.4400
Exercise price, upper limit (usd per share)	$ 7.4400
Number outstanding (shares) | shares	8,166
Weighted Average Remaining Contractual Life	5 years 4 months 6 days
Weighted Average Exercise Price (usd per share)	$ 7.4400
Aggregate Intrinsic Value | $	$ 0
Options Vested
Number Vested (shares) | shares	8,166
Weighted Average Exercise Price (usd per share)	$ 7.4400
Aggregate Intrinsic Value | $	$ 0
Exercise price $7.58
Options Outstanding
Exercise price, lower limit (usd per share)	$ 7.5800
Exercise price, upper limit (usd per share)	$ 7.5800
Number outstanding (shares) | shares	1,289
Weighted Average Remaining Contractual Life	8 years 9 months 15 days
Weighted Average Exercise Price (usd per share)	$ 7.5800
Aggregate Intrinsic Value | $	$ 0
Options Vested
Number Vested (shares) | shares	1,289
Weighted Average Exercise Price (usd per share)	$ 7.5800
Aggregate Intrinsic Value | $	$ 0
Exercise price $8.66
Options Outstanding
Exercise price, lower limit (usd per share)	$ 8.6600
Exercise price, upper limit (usd per share)	$ 8.6600
Number outstanding (shares) | shares	3,641
Weighted Average Remaining Contractual Life	6 years 5 months 5 days
Weighted Average Exercise Price (usd per share)	$ 8.6600
Aggregate Intrinsic Value | $	$ 0
Options Vested
Number Vested (shares) | shares	3,641
Weighted Average Exercise Price (usd per share)	$ 8.6600
Aggregate Intrinsic Value | $	$ 0

Stock Option Plan - Stock-Based

Stock Option Plan - Stock-Based Compensation Associated with Awards to Employees Narrative (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price after adjustment (usd per share)	$ 5
2006 Stock Option Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted (shares)	563,810		271,414
Number outstanding (shares)	1,378,546
Outstanding options repriced (usd per share)	$ 5.2100
Exercise price after adjustment (usd per share)	$ 5.21		$ 6.76	$ 6.49
2006 Stock Option Plan | Exercise price $5.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding (shares)	743,736
Outstanding options repriced (usd per share)	$ 5
Employee Stock Option | 2006 Stock Option Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted (shares)	563,810
Exercise price after adjustment (usd per share)	$ 5.63
Compensation expense	$ 748,807	$ 425,303
Total unrecognized compensation costs	$ 1,607,851
Period of recognition for costs not yet recognized	2 years 7 months 1 day
Fair value of employee options vested	$ 666,843	$ 587,843

Stock Option Plan - Schedule 58

Stock Option Plan - Schedule of Stock Option Plan Fair Value Valuation Assumptions, Employees (Details) - 2006 Stock Option Plan - Employee Stock Option	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Expected term (in years)	5 years 2 months 19 days	5 years 7 months 24 days
Expected volatility (percent)	46.00%	49.00%
Risk-free interest rate, minimum	1.17%	1.43%
Risk-free interest rate, maximum	1.54%	1.74%
Dividend yield	0.00%	0.00%

Stock Option Plan - Stock-Bas59

Stock Option Plan - Stock-Based Compensation Associated with Awards to Non-employees Narrative (Details) - USD ($)	1 Months Ended		9 Months Ended
	Aug. 31, 2016	Apr. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jul. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price after adjustment (usd per share)			$ 5
Nonemployee Stock Option | Board Adviser
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted to nonemployees (shares)		99,312
Weighted average exercise price, options granted (usd per share)		$ 7.57
Exercise price after adjustment (usd per share)					$ 5
Compensation expense			$ 104,866	$ 39,489
Total unrecognized compensation costs			$ 580,947
Period of recognition for costs not yet recognized			3 years 3 months 15 days
Exercise price $5.57 | Nonemployee Stock Option | Board Adviser
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted to nonemployees (shares)	40,608
Exercise price after adjustment (usd per share)	$ 5.57
Exercise price $5.9525 | Nonemployee Stock Option | Board Adviser
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted to nonemployees (shares)	112,651
Exercise price after adjustment (usd per share)	$ 5.5925

Stock Option Plan - Schedule 60

Stock Option Plan - Schedule of Stock Option Plan Fair Value Valuation Assumptions, Nonemployees (Details) - Board Adviser - Nonemployee Stock Option	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 11 months 19 days	5 years 8 months 1 day
Expected volatility (percent)	47.00%	49.00%
Risk-free interest rate		1.43%
Dividend yield (percent)	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.29%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.35%

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Match per employee contribution (percent)	100.00%
Match per employee contribution	$ 1,000
Employer contributions	$ 41,496	$ 48,183

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Earnings Per Share [Abstract]
Net loss	$ (3,921,958)	$ (3,667,206)	$ (17,004,551)	$ (11,693,609)	$ (14,494,248)
Accretion of redeemable convertible preferred stock	0	(20,000)	0	(63,117)
Net loss attributable to common stockholders	$ (3,921,958)	$ (3,687,206)	$ (17,004,551)	$ (11,756,726)
Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted	9,256,362	385,271	4,030,810	385,271
Net loss per share attributable to common stockholders, basic and diluted (usd per share)	$ (0.42)	$ (9.57)	$ (4.22)	$ (30.52)

Net Loss per Share - Schedule63

Net Loss per Share - Schedule of Weighted-average Common Stock Equivalents Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Convertible preferred stock (if converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average common stock equivalents excluded from net loss per share (shares)	0	3,611,857	0	3,611,857
Stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average common stock equivalents excluded from net loss per share (shares)	84,428	66,924	84,428	66,924
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average common stock equivalents excluded from net loss per share (shares)	1,378,546	873,107	1,378,546	873,107